The Filing Desk

Dianthus Therapeutics vs Xenon Pharmaceuticals

Dianthus Therapeutics DNTH · Xenon Pharmaceuticals XENE · Pharmaceuticals

Xenon Pharmaceuticals reported revenue of $8 million in fiscal 2025, 3.8 times Dianthus Therapeutics' $2 million in fiscal 2025. Dianthus Therapeutics had an operating margin of -8739.3%, against -4974.3% at Xenon Pharmaceuticals. Free cash flow was −$129 million at Dianthus Therapeutics and −$280 million at Xenon Pharmaceuticals.

Side by side

Dianthus TherapeuticsXenon Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$2M$8M
Revenue growth−67.3%—
Revenue growth a year, last 5 years—−25.3%
Gross margin——
Operating margin−8,739.3%−4,974.3%
Net margin−7,973.3%−4,612.1%
Free cash flow−$129M−$280M
Free cash flow margin−6,349.4%−3,732.2%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count15.9%1.7%
Last close$91.81$40.48
P/E at the last close——
Insider trades, last 12 monthssold $79.2 millionsold $22.0 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Dianthus TherapeuticsXenon Pharmaceuticals
Operating margin
Percent of revenue
Dianthus TherapeuticsXenon Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Dianthus TherapeuticsXenon Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Dianthus Therapeutics and Xenon Pharmaceuticals pages.